FDA clears Alma's handpiece upgrade for skin rejuvenation systems
August 5, 2008 -- Alma Lasers Ltd. (Caesarea, Israel) has announced U.S. Food and Drug Administration (FDA) clearance and immediate availability of the Pixel CO2 OMNIFIT handpiece. The unit, an upgrade to physicians' existing CO2 skin resurfacing lasers, is designed to provide impressive results with a fraction of the downtime compared to other treatments -- and saves the cost of replacing a legacy laser.
August 5, 2008 -- Alma Lasers Ltd. (Caesarea, Israel) has announced FDA clearance and immediate availability of the Pixel CO2 OMNIFIT handpiece. The Pixel CO2 OMNIFIT is Alma's newest offering in skin rejuvenation and it is an upgrade to physicians' existing CO2 skin resurfacing lasers. It is designed to provide patients with impressive results with just a fraction of the downtime compared to current treatments, and for significantly less money than replacing their current laser.
The Pixel CO2 OMNIFIT handpiece promises to fit onto most existing CO2 lasers and deliver a high degree of efficacy without the side effects or significant downtime associated with traditional CO2 resurfacing. It combines Alma's proprietary and proven Pixel fractional technology with a standard CO2 resurfacing laser. The unit targets treatment of aged, photo-damaged, and acne-scarred skin with minimal patient redness, irritation or downtime.
The Pixel CO2 OMNIFIT handpiece takes ablative patient downtime from 30 days to approximately three, making the procedure as appealing as many non-invasive approaches.
"I have had outstanding results treating my patients with fractionated CO2 skin resurfacing, says Dr. Benjamin J. Raab, Assistant Professor of Clinical Dermatology at Northwestern University Medical School and a Board Certified Dermatologist. "This will soon become the treatment of choice for patients seeking significant cosmetic improvements for aging and photo-damage without complications or prolonged healing time."
According to Howard Kelly, CEO of Alma Lasers, "This latest regulatory milestone allows us to continue to build on the success we have had with meeting physicians' needs for innovative and patient-focused solutions in the current aesthetic treatment marketplace."